Home » ReGenX, Audentes Team Up to Develop Rare Muscle Disease Treatments
ReGenX, Audentes Team Up to Develop Rare Muscle Disease Treatments
ReGenX and Audentes have decided to work together in order to develop and market new drugs to treat an X-linked disorder called myotubular myopathy. The companies will be focusing on NAV vectors, which use recombinant virus to deliver genes to human cells.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May